This Analyst Cuts I-Mab’s Price Target By 43%
I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.
Bluebird’s Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
The FDA has approved Bluebird bio Inc’s (NASDAQ:BLUE) Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed for…
Analyst Sees Deteriorated Treatment Effect Of Blueprint’s Much Awaited Mastocytosis Data
Earlier today, Blueprint Medicines Corporation (NASDAQ: BPMC) released the long-awaited pivotal PIONEER dataset in Indolent Systemic Mastocytosis (ISM). The topline data indicates that…
Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
As the U.S. plans to get out of the crisis phase, the Biden administration said it would stop buying…
Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial
Sanofi SA (NASDAQ:SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5…
What’s Going On With Teladoc Health Shares Today?
Shares of Teladoc Health Inc. (NYSE: TDOC) are trading lower today following an analyst downgrade.
Why Is It Moving?
CVS Health, Walmart & Walgreens Ordered To Pay $650.6M In Opioid Case: Reuters
Pharmacy operators CVS Health Corp (NYSE:CVS), Walmart Inc (NYSE:WMT), and Walgreens Boots Alliance Inc (NASDAQ:WBA) will be required to pay $650.6 million to…
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
CSL (OTC:CSLLY) announced topline Phase 3 results for garadacimab (CSL312) for hereditary angioedema (HAE). HAE is a rare genetic condition that…
Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review
Kate Hermans has taken over the reins of Ambrx Biopharma Inc (NASDAQ:AMAM) as interim CEO following the abrupt departure of Feng Tian,…
As The Only Monkeypox Maker Struggles, This Small Cap Plans To Develop Novel Shot
Blue Water Vaccines Inc (NASDAQ: BWV)